Clik here to view.
Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia
GHENT, Belgium Cerba Research, a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a...
View ArticleClik here to view.
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial...
PALO ALTO, Calif. & SHANGHAI & PRINCETON, N.J. LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and...
View ArticleClik here to view.
BridgeBio与联拓生物宣布，Infiglatinib在用于胃癌及其他晚期实体瘤的2a期临床试验中完成中国首例患者给药
帕罗奥图（美国加利福尼亚州）、上海和普林斯顿（美国新泽西州） (美国商业资讯)–联拓生物，一家专注于为中国和亚洲主要市场的患者带来颠覆性药物的生物制药公司，与BridgeBio Pharma股份有限公司（纳斯达克交易代码：BBIO）今日宣布，infigratinib...
View ArticleClik here to view.
Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19...
SYDNEY Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil...
View ArticleClik here to view.
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for...
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) today announced Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX®...
View ArticleClik here to view.
RubrYc Therapeutics宣布与iBio, Inc.达成A2轮优先股权融资、合作协议及RTX-003许可
加州圣卡洛斯 (美国商业资讯)–RubrYc Therapeutics, Inc. (“RubrYc”)和iBio, Inc. (“iBio”, NYSEA: IBIO)今天宣布完成RubrYc的A2轮优先股融资，以及针对表位靶向抗体疗法研发和商业化的伴随许可和合作协议。通过本次交易，iBio凭借其对RubrYc的A2轮优先股权的750万美元投资成为该公司重要战略投资者，加入由Third...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan...
View ArticleClik here to view.
Noxopharm的I期临床试验显示新冠肺炎患者有抗炎应答
悉尼 (美国商业资讯)–澳大利亚临床阶段药物开发公司Noxopharm (ASX:NOX)已发布其NOXCOVID I期临床试验的初步头条数据，该试验旨在研究TBK1（TANK结合激酶1）抑制剂idronoxil...
View ArticleClik here to view.
Clik here to view.
Noxopharm Preclinical Data Further Supports Anti-Inflammatory Role of...
SYDNEY Australian clinical-stage drug development company Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active...
View ArticleClik here to view.
ルーブリック・セラピューティクスがシリーズA2の優先株式資金調達、iBioとの提携およびRTX-003のライセンス供与を発表
米カリフォルニア州サンカルロス （ビジネスワイヤ） — ルーブリック・セラピューティクス(「ルーブリック」)とiBio（アイバイオ） (「iBio」、NYSEA:...
View ArticleClik here to view.
Clik here to view.
Noxopharm的临床前数据进一步支持Idronoxil在新冠肺炎治疗中的抗炎作用
悉尼 (美国商业资讯)–澳大利亚临床阶段药物开发公司Noxopharm (ASX:NOX)报告了一组临床前数据，这些数据进一步支持了实验性抗癌药物idronoxil（Veyonda®的活性成分）作为抗炎药物用于新冠肺炎早期治疗的功效。公司近期与澳大利亚哈德逊医学研究所（Hudson Institute of Medical...
View ArticleClik here to view.
Ligand’s Partner Gloria Biosciences Receives Approval in China for...
EMERYVILLE, Calif. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products...
View ArticleClik here to view.
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
SEATTLE HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed...
View ArticleClik here to view.
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Phase 3 PANTHER (Pevonedistat-3001) study did not achieve...
View ArticleClik here to view.
武田发布PANTHER 3期(Pevonedistat-3001)试验的最新消息
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（简称“武田”）今天宣布，PANTHER...
View ArticleClik here to view.
Clik here to view.
ロズウェルパーク総合がんセンターがインビボスクライブのLymphoTrackソフトウエアライセンスをプラグアンドプレイのパイプライン用に取得
サンディエゴ （ビジネスワイヤ） — 技術駆使型の国際企業として患者ケアを最適化して世界中で医薬品承認を加速させるクラス最高の製品とサービスによって精密診断に傾注するインビボスクライブは本日、重要なソフトウエアのライセンスと2つの新しいMRD臨床サービスについて発表しました。...
View ArticleClik here to view.
Roswell Park综合癌症中心获得Invivoscribe面向即插即用管线用途的LymphoTrack软件的许可
圣迭戈 (美国商业资讯)–Invivoscribe, Inc.是一家技术驱动型跨国公司，专注于精准诊断试剂，其所提供的一流产品和服务可优化患者诊疗，加速药物在世界各国的审批过程。公司今天宣布售出关键软件和两种新MRD临床服务的许可。 纽约Roswell Park综合癌症中心Sean...
View Article